PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'German Center for Cardiovascular Research (DZHK), Partner Site Hamburg-Kiel-Lübeck, 20251 Hamburg, Germany.\', \'Department of Cardiology, University Heart & Vascular Center Hamburg, 20251 Hamburg, Germany.\', \'Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.\', \'Division of Infectious Diseases, First Department of Medicine, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.\', \'Department of Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany.\', \'German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, 20359 Hamburg, Germany.\', \'Adrenomed AG, 16761 Hennigsdorf, Germany.\', \'SphingoTec GmbH, 16761 Hennigsdorf, Germany.\', \'4TEEN4 Pharmaceuticals GmbH, 16761 Hennigsdorf, Germany.\', \'Department of Intensive Care and Intermediate Care, University Hospital RWTH Aachen, 52074 Aachen, Germany.\', \'Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.\']
?:citedBy
  • -1
?:creator
?:doi
  • E117110.3390/biom10081171
?:doi
?:hasPublicationType
?:journal
  • Biomolecules
is ?:pmid of
?:pmid
?:pmid
  • 32796765
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.552
?:rankingScore_hIndex
  • 28
is ?:relation_isRelatedTo_publication of
?:title
  • Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab (HAM8101).
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all